Navigation Links
Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs

hat regulates the biosynthesis of the inflammatory cytokines TNF, IL-6 and IL-1. Array scientists have discovered potent MEK inhibitors that interfere with these biosynthetic processes. We have previously advanced one MEK inhibitor, ARRY-886, into clinical development for the treatment of cancer. Given our experience with the safety profile of MEK inhibitors, we believe inhibition of MEK will have broad applications in diseases driven by IL-1 and TNF. ARRY-162, an orally active MEK inhibitor, has shown significant efficacy and is well tolerated in preclinical models of human arthritis and other inflammatory diseases.

About ARRY-797 / Targeting p38 for Inflammation and Cancer

P38 is a kinase target that regulates the production of numerous pro-inflammatory cytokines, in particular, TNF, IL-6 and IL-1. These cytokines can also act as cellular growth factors and are often up-regulated in certain cancers including prostate, ovarian and multiple myeloma. Additionally, p38 may play a role in certain resistance mechanisms or metastatic progression in cancer.

About Array BioPharma:

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life-threatening and debilitating diseases. Our proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

Array BioPharma's Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to future clinical test
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... MicroDose Technologies,Inc. (MicroDose) today announced that the first ... Inc., through a Merck affiliate, has been,achieved, triggering ... MicroDose,s dry powder inhaler (DPI) technology announced in ... of a Phase I clinical,study of an investigational ...
... -Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular ... ... SUNNYVALE, Calif., Aug. 5 Icon Bioscience, Inc., (IBI),a privately ... its Phase I clinical trial to assess the,safety and efficacy of ...
Cached Medicine Technology:MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc. 2Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate 2
(Date:4/24/2014)... Pa. (April 24, 2014) - Contact lenses coated with an ... lens-related infections, reports a study in Optometry and ... Academy of Optometry . The journal is published by ... Wolters Kluwer Health . , Studies in animals and now ... the antimicrobial peptide melimine, according to the new research by ...
(Date:4/24/2014)... before, during and after colorectal surgery cut hospital stays ... researchers who led a study of the approach at ... is easier on patients before surgery, doing away with ... prescribed. After surgery, patients are encouraged to eat and ... recoveries. , Among findings published in the May 2014 ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... the corresponding terminology, and the relevance of palliation ... publications on randomized controlled trials (RCTs). This is ... Institute for Quality and Efficiency in Health Care ... report. , Together with external experts, IQWiG analysed ... lung cancer, malignant melanoma, and pancreatic cancer. For ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
Breaking Medicine News(10 mins):Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3
... ... Success”- a new DVD , Parents with teenagers who lack motivation and direction can now ... , ... 19, 2010 -- Parents with teenagers who lack motivation and direction can now access a ...
... matched the real personalities of the profile users , ... that Internet users favor idealized virtual identities, a new ... such as Facebook create profiles that stick closely to ... be more interested in fostering real communication and connections ...
... ... ... ... ...
... ... Morristown motorist and developed tinnitus, or severe ringing in her ears; she was granted compensation ... ... mail carrier represented by East Tennessee attorney Brack Terry of Terry, Terry & Stapleton ...
... ... snap. After one of the coldest Januarys in thirty years typical gas and electricity bills are ... ... energy bills of more than £200 this month because of the cold snap. After one of ...
... Contrast-enhanced magnetic resonance imaging (MRI) may help physicians differentiate ... and wrist enabling more targeted therapies unique to each ... of the American Journal of Roentgenology . Contrast-enhanced ... internal bodily structures. Rheumatoid ...
Cached Medicine News:Health News:Teen Motivation - with the 'Formula for Success' - a New DVD 2Health News:Facebook Profiles Don't Stretch the Truth 2Health News:Facebook Profiles Don't Stretch the Truth 3Health News:Facebook Profiles Don't Stretch the Truth 4Health News:MDS Announces Substantial Issuer Bid 2Health News:MDS Announces Substantial Issuer Bid 3Health News:MDS Announces Substantial Issuer Bid 4Health News:MDS Announces Substantial Issuer Bid 5Health News:MDS Announces Substantial Issuer Bid 6Health News:East Tennessee Attorney Brack Terry Obtains $120,000 Jury Award For Injured Mail Carrier 2Health News:It's Snow Joke as UK Gas and Electricity Bills Hit Record Highs -- Energyhelpline Calls for “Significant” Price Cuts 2Health News:Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis 2
Angled for temporal approach. Wire 14 mm rounded blades for patient comfort. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Fenestrated 14 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: